Abstract 6163
Background
Dexamethasone are often administered to prevent chemotherapy induced nausea and vomiting. The aim of this study was to assess the incidence of, and factors associated with, steroid induced metabolic syndrome in cancer patients receiving high emetic risk chemotherapy with antiemetic dexamethasone therapy.
Methods
This study was conducted retrospectively chart review of 356 patients who received high emetic risk chemotherapy with dexamethasone, aprepitant, and 5-HT3 antagonist between September 2015 and December 2017 at Chung-Ang University College of Medicine. Fasting plasma glucose levels. systolic blood pressure, diastolic blood pressure, triglyceride, HDL for the diagnosis of metabolic syndrome were performed before chemotherapy and 6 months after the start of chemotherapy.
Results
In total, 256 patients met the inclusion criteria and were included in analysis. The incidence of newly diagnosis metabolic syndrome was 17.5% (45 patients) after chemotherapy. The incidence of newly diagnosis diabetes and hypertension was 5.8% (15 patients), 26.2% (67 patients) after 6 months follow up. The mean metabolic syndrome score was 1.4 (range: 0-4) after chemotherapy. Multivariate analysis showed significant association of the incidence of streroid induced metabolic syndrome with BMI ≥ 25 (OR = 3.497, 95% CI = 1.064 – 11.494, p = 0.039) and colorectal cancer (OR = 0.088, 95% CI = 0.010-0.731, p = 0.024).
Conclusions
The incidence of steroid-induced metabolic syndrome after antiemetic dexamethasone therapy was high (17.4%). Therefore, we suggested that carefully measure glucose as well as LDL, triglyceride, blood pressure during antiemetic dexamethasone therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4526 - Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)
Presenter: Jessica Beaziz
Session: Poster Display session 1
Resources:
Abstract
1214 - Neo-adjuvant (NA) Imatinib for gastrointestinal stromal tumours (GISTs): What is the optimal length of treatment?
Presenter: Tom Wilson
Session: Poster Display session 1
Resources:
Abstract
2690 - Gastrointestinal Stromal Tumours (GIST) in adolescents and young adults (AYA)
Presenter: Nikki Ijzerman
Session: Poster Display session 1
Resources:
Abstract
4558 - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy
Presenter: Amandine Crombe
Session: Poster Display session 1
Resources:
Abstract
2751 - Radiomics of gastrointestinal stromal tumors; risk classification based on computed tomography images – a pilot study
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
2737 - Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
1282 - The immune landscape of chondrosarcoma reveals an anti inflammatory environment
Presenter: Iseulys Richert
Session: Poster Display session 1
Resources:
Abstract
1572 - Impact of Immunotherapy and Targeted Therapy on Tumor Growth Rate in Sarcoma
Presenter: Esmail Al-ezzi
Session: Poster Display session 1
Resources:
Abstract
3414 - DNA methylation profiles of angiosarcoma subtypes.
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)
Presenter: Daniele Fanale
Session: Poster Display session 1
Resources:
Abstract